Home ETF List About

Portfolio Holdings Detail for ISIN IE00BHZPJ890
Stock Name / FundiShares MSCI USA ESG Enhanced UCITS ETF USD (Dist)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity Type
Entity LEI 549300ZP07LMR36K1T02
ETF TickerEEDG(GBP) LSE
ETF TickerEEDS(USD) LSE
ETF TickerEEDG.LS(GBP) CXE
ETF TickerEEDS.LS(USD) CXE
ETF TickerOM3L.DE(EUR) CXE
ETF TickerEEDG.L(GBP) LSE
ETF TickerEEDS.L(GBP) LSE

Holdings detail for REGN

Stock NameRegeneron Pharmaceuticals Inc
TickerREGN(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS75886F1075
LEI549300RCBFWIRX3HYQ56

Show aggregate REGN holdings

News associated with REGN

Regeneron And Sanofi : CHMP Recommends EU Approval Of Dupixent For Chronic Spontaneous Urticaria
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the European Union for treating c - 2025-09-22 02:12:20
Peek Under The Hood: JEPQ Has 10% Upside
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-09-08 08:26:56
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) have been given an average recommendation of “Moderate Buy” by the twenty-six analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have assigned a buy rating and three […] - 2025-08-26 02:16:48
LABU, INCY, UTHR, REGN: ETF Outflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have detected an approximate $67.3 million dollar outflow -- that's a 9.4% dec - 2025-08-20 12:04:03
Regeneron Pharmaceuticals (NASDAQ:REGN) versus Cadrenal Therapeutics (NASDAQ:CVKD) Head-To-Head Analysis
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) and Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings. Volatility and Risk Regeneron Pharmaceuticals has a beta […] - 2025-08-20 02:22:48
Truist Financial Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $812.00
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target reduced by Truist Financial from $940.00 to $812.00 in a research note published on Monday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. REGN has been the topic of several other reports. The Goldman Sachs Group dropped their price target on […] - 2025-08-14 03:00:52
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Raised by Blair William & Co. IL
Blair William & Co. IL lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.2% in the 1st quarter, Holdings Channel reports. The fund owned 1,282 shares of the biopharmaceutical company’s stock after buying an additional 27 shares during the period. Blair William & Co. IL’s holdings in Regeneron Pharmaceuticals were worth […] - 2025-08-11 06:26:50
Harbour Investments Inc. Sells 32 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Harbour Investments Inc. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 7.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 403 shares of the biopharmaceutical company’s stock after selling 32 shares during the quarter. Harbour Investments Inc.’s holdings in […] - 2025-08-07 09:40:47
We Did The Math SPYX Can Go To $58
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-07 08:58:54
409 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Arkadios Wealth Advisors
Arkadios Wealth Advisors purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 409 shares of the biopharmaceutical company’s stock, valued at approximately $259,000. Several other institutional investors and hedge funds also […] - 2025-08-07 05:38:53
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, BMO Capital Markets Analyst Says
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target upped by stock analysts at BMO Capital Markets from $600.00 to $640.00 in a research report issued on Monday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target indicates a potential upside of 12.30% from […] - 2025-08-06 03:12:48
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $828.86 Consensus Target Price from Brokerages
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty-four ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, fifteen have assigned a buy recommendation and two […] - 2025-08-04 02:59:01
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 19:31:54
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:40:40
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:35:36
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:02:25
Nasdaq 100 Movers: MRVL, REGN
In early trading on Friday, shares of Regeneron Pharmaceuticals, topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.6%. Year to date, Regeneron Pharmaceuticals, has lost about 20.7% of its value. And the worst performing Nasdaq 100 co - 2025-08-01 11:30:09
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Choreo LLC
Choreo LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 0.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,746 shares of the biopharmaceutical company’s stock after acquiring an additional 32 shares during the period. Choreo LLC’s holdings in Regeneron Pharmaceuticals […] - 2025-07-24 07:22:56
Crestwood Advisors Group LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Crestwood Advisors Group LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 467 shares of the biopharmaceutical company’s stock after purchasing an additional 25 shares during the quarter. Crestwood Advisors Group […] - 2025-07-24 05:47:12
Kestra Private Wealth Services LLC Has $1.31 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Kestra Private Wealth Services LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 6.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,058 shares of the biopharmaceutical company’s stock after buying an additional 132 shares during the quarter. […] - 2025-07-23 07:50:58
Larson Financial Group LLC Has $34,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Larson Financial Group LLC lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 34.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 53 shares of the biopharmaceutical company’s stock after selling 28 shares during the quarter. Larson […] - 2025-07-23 06:30:53
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Alps Advisors Inc.
Alps Advisors Inc. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 71.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 530 shares of the biopharmaceutical company’s stock after purchasing an additional 220 shares during the quarter. Alps Advisors Inc.’s […] - 2025-07-17 05:50:54
Stratos Wealth Partners LTD. Sells 115 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Stratos Wealth Partners LTD. trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 18.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 506 shares of the biopharmaceutical company’s stock after selling 115 shares during the period. Stratos Wealth Partners […] - 2025-07-16 04:58:54
Allworth Financial LP Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Allworth Financial LP trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 14.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 821 shares of the biopharmaceutical company’s stock after selling 137 shares during the period. Allworth Financial […] - 2025-07-15 08:20:00
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $584.00
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target increased by UBS Group from $560.00 to $584.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock. Several other research analysts also recently commented on REGN. BMO Capital Markets reduced their price objective on Regeneron […] - 2025-07-14 03:30:48
Brown Advisory Inc. Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Brown Advisory Inc. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,269 shares of the biopharmaceutical company’s stock after selling 247 shares during the quarter. Brown Advisory Inc.’s […] - 2025-07-13 05:54:54
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Cut by D.A. Davidson & CO.
D.A. Davidson & CO. reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.8% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 732 shares of the biopharmaceutical company’s stock after selling 21 shares during the quarter. D.A. […] - 2025-07-11 05:32:52
Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) PT at $813.57
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has received an average recommendation of “Moderate Buy” from the twenty-five ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and three have issued […] - 2025-07-10 03:07:00
DAVENPORT & Co LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
DAVENPORT & Co LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 427 shares of the biopharmaceutical company’s stock, valued at approximately $271,000. A number of other institutional […] - 2025-07-09 05:11:22
Bessemer Group Inc. Sells 3,860 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Bessemer Group Inc. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 76.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,218 shares of the biopharmaceutical company’s stock after selling 3,860 shares during the period. Bessemer Group […] - 2025-07-01 05:46:52

iShares MSCI USA ESG Enhanced UCITS ETF USD (Dist) REGN holdings

DateNumber of REGN Shares HeldBase Market Value of REGN SharesLocal Market Value of REGN SharesChange in REGN Shares HeldChange in REGN Base ValueCurrent Price per REGN Share HeldPrevious Price per REGN Share Held
2025-09-29 (Monday)11,743USD 6,584,887USD 6,584,887
2025-09-26 (Friday)11,741USD 6,620,750USD 6,620,750
2025-09-25 (Thursday)11,843REGN holding increased by 55USD 6,578,905REGN holding decreased by -222535USD 6,578,90555USD -222,535 USD 555.51 USD 576.98
2025-09-24 (Wednesday)11,788USD 6,801,440USD 6,801,440
2025-09-18 (Thursday)11,406REGN holding increased by 28USD 6,828,886REGN holding increased by 167067USD 6,828,88628USD 167,067 USD 598.71 USD 585.5
2025-09-17 (Wednesday)11,378REGN holding increased by 43USD 6,661,819REGN holding increased by 143514USD 6,661,81943USD 143,514 USD 585.5 USD 575.06
2025-09-16 (Tuesday)11,335USD 6,518,305REGN holding increased by 27997USD 6,518,3050USD 27,997 USD 575.06 USD 572.59
2025-09-15 (Monday)11,335REGN holding increased by 22USD 6,490,308REGN holding increased by 155028USD 6,490,30822USD 155,028 USD 572.59 USD 560
2025-09-12 (Friday)11,313REGN holding increased by 17USD 6,335,280REGN holding decreased by -83107USD 6,335,28017USD -83,107 USD 560 USD 568.2
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of REGN by Blackrock for IE00BHZPJ890

Show aggregate share trades of REGN

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-09-25BUY55 555.510* 667.51
2025-09-18BUY28 598.710* 667.88
2025-09-17BUY43 585.500* 668.34
2025-09-15BUY22 572.590* 669.39
2025-09-12BUY17 560.000* 670.00
2025-09-11SELL-54 568.200* 670.57 Profit of 36,211 on sale
2025-09-10BUY10 555.830* 671.22
2025-09-09BUY13 556.530* 671.87
2025-08-27BUY8 586.960* 672.89
2025-08-21BUY2 598.160* 673.81
2025-08-19BUY6 571.780* 674.89
2025-07-21BUY2 545.530* 675.66
2025-07-18BUY57 542.520* 676.45
2025-07-17BUY12 550.000* 677.21
2025-07-16BUY129 547.930* 677.99
2025-07-15BUY110 547.960* 678.78
2025-07-03SELL-8 547.360* 680.39 Profit of 5,443 on sale
2025-07-02SELL-60 547.740* 681.21 Profit of 40,872 on sale
2025-06-30SELL-6 525.000* 682.18 Profit of 4,093 on sale
2025-06-27BUY8 521.000* 683.19
2025-06-26BUY4 521.000* 684.21
2025-06-25BUY8 520.290* 685.24
2025-06-24SELL-6 522.270* 686.28 Profit of 4,118 on sale
2025-06-17SELL-9 508.860* 692.03 Profit of 6,228 on sale
2025-06-13SELL-2 529.240* 694.24 Profit of 1,388 on sale
2025-06-12BUY3 521.840* 695.40
2025-06-06SELL-14 493.220* 700.43 Profit of 9,806 on sale
2025-06-05SELL-22 483.070* 701.94 Profit of 15,443 on sale
2025-06-04SELL-29 484.930* 703.45 Profit of 20,400 on sale
2025-06-03BUY6 487.860* 704.97
2025-06-02SELL-2 490.810* 706.49 Profit of 1,413 on sale
2025-05-30BUY11 490.280* 708.03
2025-05-29SELL-6 605.390* 708.77 Profit of 4,253 on sale
2025-05-28SELL-4 591.850* 709.62 Profit of 2,838 on sale
2025-05-23SELL-18 588.340* 712.20 Profit of 12,820 on sale
2025-05-22BUY1 596.850* 713.07
2025-05-21SELL-5 604.620* 713.88 Profit of 3,569 on sale
2025-05-20BUY22 614.790* 714.63
2025-05-16SELL-9 594.320* 716.47 Profit of 6,448 on sale
2025-05-15BUY1 584.990* 717.48
2025-05-14BUY18 571.360* 718.63
2025-05-13BUY67 574.160* 719.76
2025-05-12BUY53 575.630* 720.91
2025-05-09BUY17 527.780* 722.45
2025-05-08SELL-32 547.670* 723.86 Profit of 23,164 on sale
2025-05-07BUY47 560.930* 725.19
2025-05-06BUY11 558.520* 726.55
2025-05-02BUY3 605.610* 728.59
2025-05-01SELL-1 590.000* 729.75 Profit of 730 on sale
2025-04-29BUY1 568.910* 732.24
2025-04-28SELL-251 610.860* 733.29 Profit of 184,056 on sale
2025-04-25SELL-2 602.640* 734.43 Profit of 1,469 on sale
2025-04-24SELL-31 599.760* 735.61 Profit of 22,804 on sale
2025-04-23SELL-11 587.850* 736.92 Profit of 8,106 on sale
2025-04-22SELL-14 585.490* 738.27 Profit of 10,336 on sale
2025-04-16SELL-39 549.280* 744.90 Profit of 29,051 on sale
2025-04-11BUY40 554.180* 750.15
2025-04-10BUY12 546.390* 752.11
2025-04-09BUY15 576.720* 753.81
2025-04-08SELL-17 556.810* 755.74 Profit of 12,848 on sale
2025-04-07BUY33 572.780* 757.56
2025-04-04BUY27 573.450* 759.40
2025-04-02BUY25 625.600* 760.75
2025-04-01BUY16 617.000* 762.21
2025-03-31SELL-86 634.230* 763.53 Profit of 65,664 on sale
2025-03-28SELL-8 637.360* 764.85 Profit of 6,119 on sale
2025-03-26BUY2 640.140* 767.55
2025-03-25BUY6 634.140* 768.98
2025-03-24BUY12 661.000* 770.16
2025-03-21BUY308 658.480* 771.38
2025-03-20BUY4 662.620* 772.59
2025-03-19SELL-29 672.360* 773.72 Profit of 22,438 on sale
2025-03-17SELL-4 678.420* 776.06 Profit of 3,104 on sale
2025-03-14SELL-8 666.870* 777.33 Profit of 6,219 on sale
2025-03-13SELL-1 680.610* 778.47 Profit of 778 on sale
2025-03-12SELL-7 689.500* 779.53 Profit of 5,457 on sale
2025-03-11BUY2 718.160* 780.27
2025-03-06BUY62 698.440* 782.64
2025-03-05SELL-8 687.150* 783.85 Profit of 6,271 on sale
2025-03-03BUY6 684.870* 786.55
2025-02-28SELL-6,542 698.740* 787.70 Profit of 5,153,144 on sale
2025-02-27SELL-40 702.780* 788.83 Profit of 31,553 on sale
2025-02-26SELL-506 706.940* 789.94 Profit of 399,710 on sale
2025-02-25SELL-34 723.470* 790.85 Profit of 26,889 on sale
2025-02-24BUY50 713.250* 791.93
2025-02-21BUY26 700.330* 793.22
2025-02-20BUY6 696.020* 794.61
2025-02-19BUY4 685.660* 796.19
2025-02-18SELL-22 680.000* 797.90 Profit of 17,554 on sale
2025-02-14BUY6 673.600* 801.66
2025-02-13SELL-4 674.270* 803.62 Profit of 3,214 on sale
2025-02-12SELL-76 663.860* 805.81 Profit of 61,241 on sale
2025-02-06BUY10 722.070* 813.06
2025-02-05SELL-30 716.720* 814.69 Profit of 24,441 on sale
2025-02-03BUY4 666.850* 819.35
2025-01-30SELL-42 683.080* 824.49 Profit of 34,629 on sale
2025-01-28SELL-26 686.330* 829.69 Profit of 21,572 on sale
2025-01-27BUY12 684.710* 832.47
2025-01-24BUY22 675.790* 835.55
2025-01-23BUY22 694.640* 838.36
2024-12-09BUY4 788.000* 840.66
2024-12-06BUY62 778.000* 841.99
2024-12-04BUY46 754.260* 845.59
2024-12-03BUY26 749.570* 847.77
2024-12-02BUY60 762.340* 849.76
2024-11-29BUY6 750.220* 852.13
2024-11-27BUY2 754.870* 856.99
2024-11-26SELL-68 753.030* 862.46 Profit of 58,648 on sale
2024-11-26SELL-68 753.030* 862.46 Profit of 58,648 on sale
2024-11-25SELL-9,616 749.510* 865.52 Profit of 8,322,812 on sale
2024-11-22SELL-7 738.000* 869.06 Profit of 6,083 on sale
2024-11-21BUY168 744.500* 872.62
2024-11-19SELL-36 744.600* 880.41 Profit of 31,695 on sale
2024-11-18BUY79 762.000* 884.12
2024-11-12BUY4 821.000* 886.15
2024-11-08BUY12 828.420* 892.43
2024-11-08BUY12 828.420* 892.43
2024-11-07BUY308 824.480* 897.66
2024-11-07BUY308 824.480* 897.66
2024-11-06BUY8 816.650* 904.41
2024-11-06BUY8 816.650* 904.41
2024-11-05SELL-20 829.430* 911.23 Profit of 18,225 on sale
2024-11-05SELL-20 829.430* 911.23 Profit of 18,225 on sale
2024-11-04SELL-144 828.840* 919.47 Profit of 132,403 on sale
2024-11-04SELL-144 828.840* 919.47 Profit of 132,403 on sale
2024-11-01SELL-40 843.600* 927.90 Profit of 37,116 on sale
2024-11-01SELL-40 843.600* 927.90 Profit of 37,116 on sale
2024-10-31BUY23 838.200* 939.11
2024-10-31BUY23 838.200* 939.11
2024-10-30SELL-152 922.790* 941.44 Profit of 143,099 on sale
2024-10-30SELL-152 922.790* 941.44 Profit of 143,099 on sale
2024-10-29SELL-144 927.330* 943.79 Profit of 135,906 on sale
2024-10-29SELL-144 927.330* 943.79 Profit of 135,906 on sale
2024-10-28BUY12 928.610* 946.83
2024-10-28BUY12 928.610* 946.83
2024-10-25BUY256 933.020* 950.28
2024-10-25BUY256 933.020* 950.28
2024-10-24BUY32 928.900* 957.41
2024-10-24BUY32 928.900* 957.41
2024-10-23SELL-6 941.390* 965.42 Profit of 5,793 on sale
2024-10-23SELL-6 941.390* 965.42 Profit of 5,793 on sale
2024-10-22BUY28 962.340* 968.50
2024-10-22BUY28 962.340* 968.50
2024-10-21SELL-280 968.500* 0.00
2024-10-21SELL-280 968.500* 0.00
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of REGN

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19208,6591,635312,81266.7%
2025-09-18236,4853,679387,51961.0%
2025-09-17229,191716370,89561.8%
2025-09-16173,632584271,02064.1%
2025-09-15204,491251334,49661.1%
2025-09-12117,50433222,76052.7%
2025-09-11125,4783,137286,51643.8%
2025-09-10195,068481339,88557.4%
2025-09-09129,168994274,52047.1%
2025-09-08250,895396527,06247.6%
2025-09-05170,149290289,56658.8%
2025-09-04188,2272,103360,61952.2%
2025-09-03185,679344438,11142.4%
2025-09-02191,954138476,28840.3%
2025-08-29133,226685236,72656.3%
2025-08-28116,5602,177256,67545.4%
2025-08-27113,719465243,83646.6%
2025-08-26210,376450400,19952.6%
2025-08-25149,13068363,37741.0%
2025-08-22211,8223,244701,77030.2%
2025-08-21257,4923,416446,43957.7%
2025-08-20327,738572559,13358.6%
2025-08-19118,4722,191324,31136.5%
2025-08-18146,282388277,90952.6%
2025-08-15209,9233,375441,75247.5%
2025-08-14157,5693,623429,32736.7%
2025-08-13111,342233362,78630.7%
2025-08-12117,647171310,77537.9%
2025-08-11129,5132,676284,75745.5%
2025-08-08128,5591,038431,84129.8%
2025-08-07166,6481,560352,87747.2%
2025-08-06176,311624397,08944.4%
2025-08-05154,257115353,74443.6%
2025-08-04200,7581,913409,89749.0%
2025-08-01349,7753,745728,72048.0%
2025-07-31222,350476549,34440.5%
2025-07-30106,8391,689231,76146.1%
2025-07-29149,359276292,66751.0%
2025-07-28103,6871,380245,28742.3%
2025-07-25103,783556259,06940.1%
2025-07-24156,9742,397291,67753.8%
2025-07-23168,7341,708355,37247.5%
2025-07-22116,324617304,88038.2%
2025-07-2198,482900250,10739.4%
2025-07-18183,1741,051391,90946.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.